Autoimmunity and mechanism research
It is used for the study of autoimmune podocytopathy, slit diaphragm injury mechanism and multi-antigen reaction, and supplements the observation dimension of antibody spectrum.
PODOARRAY-2 · LUMINEX xMAP
PodoArray-2: Slit Diaphragm Autoantibody Testing
From a single anti-nephrin,
Toward joint observation of expanded antibody repertoires.
THE ANTIBODY PROFILE
One Dual-target Assay,
A Broader View of the Slit Diaphragm.
PodoArray-2 simultaneously detects serum anti-Podocin and anti-KIRREL1. Combined with the anti-nephrin results of SuperNAT, look at whether the autoimmune response involves multiple slit membrane antigens.
PodoArray-2 Dual target detection
anti-KIRREL1
KIRREL1-related autoantibodies
anti-Podocin
Podocin-related autoantibodies
Focus on whether the antibody profile goes beyond a single anti-nephrin; combined interpretation is not just comparing which of the two targets is positive.
RESEARCH APPLICATIONS
Interpret Antibody Profiles in Their Disease Context.
Connect serum results with pathology, clinical phenotype, and follow-up information around mechanisms of podocytopathy, slit diaphragm injury, and post-transplant relapse.
Clinical cohorts and disease progression
Combining pathological type, proteinuria, renal function and treatment response, explore the association between antibody profiles and disease phenotype and progression.
Mechanisms of recurrence after transplantation
Combining samples before and after transplantation to study changes in antibody profiles. Causes of proteinuria after transplantation still need to be simultaneously identified such as recurrence, rejection, and drug-related injury.
Research background
In a study of 213 cases of podocytopathy, anti-slit diaphragm autoantibodies were detected in 67 cases, of which approximately 25% were polyantigen reactive. This study suggests that different antibody profiles are associated with clinical phenotypes and cannot be directly used to predict individual recurrence or treatment outcomes.
View study source · JASN, 2026 ↗FROM SERUM TO SIGNAL
From Serum Samples to Dual-target Results.
Based on Luminex xMAP technology, targets are identified and fluorescent signals are read through different microsphere encodings.
- 01serum sample
- 02Dual target microsphere incubation
- 03target antibody binding
- 04fluorescent signal label
- 05xMAP reading and analysis
Controlling Background from Antigen Selection
The hydrophobic and conformation-dependent characteristics of Podocin increase the difficulty of antigen development. AlloDx passes parallel screening of different truncated fragments and adopts HSA fusion-assisted expression and conformational stabilization strategies to take into account expressibility, epitope exposure, and detection background.
In candidate antigen screening of 20 healthy human sera, the background of the novel development antigen was 144 ± 68 MFI, which was lower than the three commercially available antigens compared in this batch. The results are limited to this batch of screening conditions and are not equivalent to clinical diagnostic performance.
Assay Performance
- KIRREL1 curve fitting R²
- 0.9997
- Podocin curve fitting R²
- 0.9998
- intra-batch CV
- 7.1%–9.9%
- Batch-to-batch CV
- 8.3%–14.7%
The data comes from the methodological verification in the product information on this page; the applicable conditions are subject to the specific project description.
READ THE RESULTS TOGETHER
The Report Provides the Signals,
Combined Interpretation Reveals the Profile.
SuperNAT positive
PodoArray-2: Both Targets Negative
Within the range of detected targets, suggesting a relatively localized anti-nephrin response. Negative results do not rule out other mechanisms or that antibodies were not detected.
PodoArray-2
Either Target Positive
It indicates the presence of Podocin or KIRREL1-related reactions; the anti-nephrin results need to be combined to determine the composition of the antibody spectrum, and multiple antigen reactions cannot be determined based on just one positive result.
MFI median fluorescenceReference thresholdResult judgmentPositive/negative control
Supplementary information for autoantibody research and clinical phenotype stratification. The results need to be combined with pathology, proteinuria, renal function, treatment and follow-up; they cannot alone determine diagnosis, transplantation timing or immunosuppression regimen.
PRODUCT RESOURCES
PodoArray-2 Product Data Sheet
View the complete tri-fold page to learn about the testing process, methodological performance and research background.
Discuss Your Research and Sample Requirements
Test sample: serum. Please confirm with the technical team for sample size, storage and transportation requirements and project arrangements.
Contact AlloDx ↗Some original figures, videos and downloadable materials are provided in Chinese.